KalVista Pharmaceuticals, Inc. KALV
Updated: 8 Aug 2026
No signal published yet
We already track KalVista Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow KalVista Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow KalVista Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 11, 2026, Chiesi Group completed its acquisition of KalVista Pharmaceuticals for approximately $1.9 billion, or $27.00 per share in cash. Following the completion of the merger, KalVista became a wholly owned subsidiary of Chiesi Group and its common stock ceased trading on Nasdaq.
What Firelda Watch includes for KalVista Pharmaceuticals, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow KalVista Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow KalVista Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more